tiprankstipranks
Veracyte Inc (VCYT)
NASDAQ:VCYT
US Market
VCYT
Veracyte
RESEARCH TOOLSreports
Want to see VCYT full AI Analyst Report?

Veracyte (VCYT) Stock Forecast & Price Target

579 Followers
See the Price Targets and Ratings of:

VCYT Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
6 Buy
1 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Veracyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VCYT Stock 12 Month Forecast

Average Price Target

$45.28
▲(33.97% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $45.28 with a high forecast of $52.00 and a low forecast of $39.70. The average price target represents a 33.97% change from the last price of $33.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","53":"$53","29.75":"$29.8","37.5":"$37.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.28333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$39.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,29.75,37.5,45.25,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.09,34.54461538461539,35.99923076923077,37.45384615384616,38.90846153846154,40.363076923076925,41.81769230769231,43.27230769230769,44.72692307692308,46.181538461538466,47.636153846153846,49.09076923076923,50.54538461538462,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.09,34.027948717948725,34.96589743589744,35.90384615384616,36.841794871794875,37.779743589743596,38.71769230769231,39.65564102564103,40.593589743589746,41.53153846153847,42.46948717948718,43.4074358974359,44.34538461538462,{"y":45.28333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.09,33.59846153846154,34.10692307692308,34.61538461538462,35.12384615384616,35.6323076923077,36.14076923076924,36.64923076923077,37.15769230769231,37.66615384615385,38.174615384615386,38.683076923076925,39.191538461538464,{"y":39.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.01,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$45.28Lowest Price Target$39.70
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on VCYT
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
05/22/26
Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Decibel Cannabis Company (DBCCF)
Canaccord Genuity Analyst forecast on VCYT
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$42
Hold
24.26%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Tonix Pharma (NASDAQ: TNXP) and Regeneron (NASDAQ: REGN)
Morgan Stanley Analyst forecast on VCYT
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$37→$39.7
Sell
17.46%
Upside
Reiterated
05/12/26
Veracyte (VCYT) Gets a Sell from Morgan Stanley
Guggenheim Analyst forecast on VCYT
Subbu Nambi
Guggenheim
Guggenheim
$45
Buy
33.14%
Upside
Reiterated
05/06/26
Guggenheim Remains a Buy on Veracyte (VCYT)
William Blair Analyst forecast on VCYT
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/06/26
Veracyte Earns Buy Rating on Consistent Outperformance, Raised Guidance and Attractive Optionality From Upcoming Pipeline Launches
Needham Analyst forecast on VCYT
Michael Matson
Needham
Needham
$48
Buy
42.01%
Upside
Reiterated
05/06/26
Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Solventum Corporation (SOLV)
UBS Analyst forecast on VCYT
Lu Li
UBS
UBS
$48→$52
Buy
53.85%
Upside
Reiterated
05/06/26
Veracyte price target raised to $52 from $48 at UBSVeracyte price target raised to $52 from $48 at UBS
Jefferies Analyst forecast on VCYT
Tycho Peterson
Jefferies
Jefferies
$45
Buy
33.14%
Upside
Initiated
04/12/26
Veracyte initiated with a Buy at JefferiesVeracyte initiated with a Buy at Jefferies
Freedom Capital Markets Analyst forecast on VCYT
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
$45
Buy
33.14%
Upside
Initiated
10/16/25
Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets
Leerink Partners Analyst forecast on VCYT
Puneet Souda
Leerink Partners
Leerink Partners
$45
Buy
33.14%
Upside
Reiterated
08/07/25
Veracyte's Strong Clinical Evidence and Market Growth Justify Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on VCYT
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
05/22/26
Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Decibel Cannabis Company (DBCCF)
Canaccord Genuity Analyst forecast on VCYT
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$42
Hold
24.26%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Tonix Pharma (NASDAQ: TNXP) and Regeneron (NASDAQ: REGN)
Morgan Stanley Analyst forecast on VCYT
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$37→$39.7
Sell
17.46%
Upside
Reiterated
05/12/26
Veracyte (VCYT) Gets a Sell from Morgan Stanley
Guggenheim Analyst forecast on VCYT
Subbu Nambi
Guggenheim
Guggenheim
$45
Buy
33.14%
Upside
Reiterated
05/06/26
Guggenheim Remains a Buy on Veracyte (VCYT)
William Blair Analyst forecast on VCYT
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/06/26
Veracyte Earns Buy Rating on Consistent Outperformance, Raised Guidance and Attractive Optionality From Upcoming Pipeline Launches
Needham Analyst forecast on VCYT
Michael Matson
Needham
Needham
$48
Buy
42.01%
Upside
Reiterated
05/06/26
Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Solventum Corporation (SOLV)
UBS Analyst forecast on VCYT
Lu Li
UBS
UBS
$48→$52
Buy
53.85%
Upside
Reiterated
05/06/26
Veracyte price target raised to $52 from $48 at UBSVeracyte price target raised to $52 from $48 at UBS
Jefferies Analyst forecast on VCYT
Tycho Peterson
Jefferies
Jefferies
$45
Buy
33.14%
Upside
Initiated
04/12/26
Veracyte initiated with a Buy at JefferiesVeracyte initiated with a Buy at Jefferies
Freedom Capital Markets Analyst forecast on VCYT
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
$45
Buy
33.14%
Upside
Initiated
10/16/25
Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets
Leerink Partners Analyst forecast on VCYT
Puneet Souda
Leerink Partners
Leerink Partners
$45
Buy
33.14%
Upside
Reiterated
08/07/25
Veracyte's Strong Clinical Evidence and Market Growth Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Veracyte

3 Months
William BonelloCraig-Hallum
Success Rate
4/7 ratings generated profit
57%
Average Return
+7.21%
Copying William Bonello's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +7.21% per trade.
1 Year
Subbu NambiGuggenheim
Success Rate
8/9 ratings generated profit
89%
Average Return
+21.28%
Copying Subbu Nambi's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +21.28% per trade.
2 Years
William BonelloCraig-Hallum
Success Rate
7/7 ratings generated profit
100%
Average Return
+40.93%
Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +40.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VCYT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
9
7
8
7
11
Hold
3
3
3
2
3
Sell
3
2
2
1
2
Strong Sell
0
0
0
0
0
total
15
12
13
10
16
In the current month, VCYT has received 11 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. VCYT average Analyst price target in the past 3 months is 45.28.
Each month's total comprises the sum of three months' worth of ratings.

VCYT Financial Forecast

VCYT Earnings Forecast

Next quarter’s earnings estimate for VCYT is $0.43 with a range of $0.41 to $0.47. The previous quarter’s EPS was $0.52. VCYT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.
Next quarter’s earnings estimate for VCYT is $0.43 with a range of $0.41 to $0.47. The previous quarter’s EPS was $0.52. VCYT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.

VCYT Sales Forecast

Next quarter’s sales forecast for VCYT is $144.58M with a range of $142.90M to $147.90M. The previous quarter’s sales results were $139.07M. VCYT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.
Next quarter’s sales forecast for VCYT is $144.58M with a range of $142.90M to $147.90M. The previous quarter’s sales results were $139.07M. VCYT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.

VCYT Stock Forecast FAQ

What is VCYT’s average 12-month price target, according to analysts?
Based on analyst ratings, Veracyte Inc’s 12-month average price target is 45.28.
    What is VCYT’s upside potential, based on the analysts’ average price target?
    Veracyte Inc has 33.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VCYT a Buy, Sell or Hold?
          Veracyte Inc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Veracyte Inc’s price target?
            The average price target for Veracyte Inc is 45.28. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $39.70. The average price target represents 33.97% Increase from the current price of $33.8.
              What do analysts say about Veracyte Inc?
              Veracyte Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of VCYT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.